Galectin Therapeutics (GALT) Non Operating Interest Expenses (2018 - 2026)
Powered by 
Analysis
Galectin Therapeutics (GALT) Non Operating Interest Expenses (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.39 Bn | 131.54 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.61 Bn | 77.61 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.96 Bn | 43.96 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.97 Bn | 34.87 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.20 Bn | 31.89 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.60 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Galectin Therapeutics | 299.73 Mn | 299.73 Mn | - | 2.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.00 Mn |
| Mar 31, 2026 | 1.99 Mn |
| Dec 31, 2025 | 1.94 Mn |
| Sep 30, 2025 | 1.82 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Mar 31, 2025 | 1.74 Mn |
| Dec 31, 2024 | 1.73 Mn |
| Sep 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.05 Mn |
| Dec 31, 2023 | 847,000.00 |
| Sep 30, 2023 | 835,000.00 |
| Jun 30, 2023 | 650,000.00 |
| Mar 31, 2023 | 460,000.00 |
| Dec 31, 2022 | 308,000.00 |
| Sep 30, 2022 | 269,000.00 |
| Jun 30, 2022 | 241,000.00 |
| Mar 31, 2022 | 227,000.00 |
| Dec 31, 2021 | 272,000.00 |
| Sep 30, 2021 | 111,000.00 |